JACC. Cardiovascular interventions最新文献

{"title":"When Device Evolution Enables Strategy","authors":"Sho Nakao MD, Keisuke Yasumura MD, Amit Hooda MD, Samin K. Sharma MD, Annapoorna S. Kini MD","doi":"10.1016/j.jcin.2026.05.031","DOIUrl":"10.1016/j.jcin.2026.05.031","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2412-2413"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Prior Transcatheter Aortic Valve Replacement","authors":"Ayman R. Fath MD, Dimitrios Strepkos MD, Noah N. Williford MD, Mishita Goel MD, Eleni Kladou MD, Asaad Nakhle MD, Laura Young MD, Jaikirshan Khatri MD, Khaldoon Alaswad MD, Emmanouil S. Brilakis MD, PhD","doi":"10.1016/j.jcin.2026.07.020","DOIUrl":"10.1016/j.jcin.2026.07.020","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2404-2406"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clopidogrel or Aspirin for Long-Term Secondary Prevention in Patients With Diabetes","authors":"Francesco Franchi MD, Fabiana Rollini MD","doi":"10.1016/j.jcin.2026.06.033","DOIUrl":"10.1016/j.jcin.2026.06.033","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2345-2347"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bronchial Artery Perforation From Transradial Catheterization Treated With Coil Embolization","authors":"Takashi Kataoka MD, Satoshi Terashima MD, Ryoga Kawabata MD, Kazuki Watarai MD, Shinichiro Takeda MD, Syun Matsunaga MD, Kunihiko Takahara MD, PhD, Kazuhiro Harada MD, PhD, Tomoyuki Nagao MD, PhD, Norihiro Shinoda MD, PhD, Ken Harada MD, PhD, Toyoaki Murohara MD, PhD","doi":"10.1016/j.jcin.2026.05.037","DOIUrl":"10.1016/j.jcin.2026.05.037","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2414-2416"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full Issue PDF","authors":"","doi":"10.1016/S1936-8798(26)02183-7","DOIUrl":"10.1016/S1936-8798(26)02183-7","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages I-CXXXVIII"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148958432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrashort vs Standard-Duration Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing PCI","authors":"Hendrianus Hendrianus MD,&nbsp;Diana A. Gorog MD,&nbsp;Udaya S. Tantry PhD,&nbsp;Eliano P. Navarese MD, PhD,&nbsp;Sang Yeub Lee MD, PhD,&nbsp;Jun Hwan Cho MD,&nbsp;Jinhwan Jo MD,&nbsp;Jeonghoon Bae MD, PhD,&nbsp;Sam Yeol Ha MD, PhD,&nbsp;Satoshi Honda MD, PhD,&nbsp;Satoshi Yasuda MD, PhD,&nbsp;Bambang Widyantoro MD, PhD,&nbsp;Sunarya Soerianata MD,&nbsp;Paul A. Gurbel MD,&nbsp;Sang-Wook Kim MD, PhD,&nbsp;Young-Hoon Jeong MD, PhD","doi":"10.1016/j.jcin.2026.07.012","DOIUrl":"10.1016/j.jcin.2026.07.012","url":null,"abstract":"<div><h3>Background</h3><div>The efficacy and safety of ultrashort (≤1-month) dual antiplatelet therapy (DAPT) followed by antiplatelet monotherapy remain uncertain in acute coronary syndrome (ACS) patients.</div></div><div><h3>Objectives</h3><div>This study sought to compare ultrashort vs standard-duration DAPT in patients with ACS undergoing percutaneous coronary intervention (PCI).</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of randomized controlled trials until February 15, 2026. Primary outcomes were major adverse cardiac and cerebrovascular events (MACCE), major bleeding, and net adverse clinical event (NACE). Prespecified subgroup analyses examined by ethnicity (East Asian vs non-East Asian) and abbreviation strategy (intensive: ≤1-week DAPT or clopidogrel/aspirin monotherapy vs moderate: ≥2-week DAPT, followed by ticagrelor/prasugrel monotherapy).</div></div><div><h3>Results</h3><div>Across 10 trials (n = 29,232), ultrashort DAPT did not increase MACCE risk (HR: 1.06; 95% CI: 0.93-1.20; <em>P</em> = 0.38; <em>I</em>² = 24%), with higher MACCE risk observed in ST-segment elevation myocardial infarction (STEMI) but not non-ST-segment elevation ACS (NSTE-ACS), and significantly reduced major bleeding (HR: 0.47; 95% CI: 0.35-0.64; <em>P</em> &lt; 0.00001; <em>I</em>² = 44%), resulting in a net clinical benefit (HR: 0.83; 95% CI: 0.72-0.97; <em>P</em> = 0.02; <em>I</em>² = 61%). Bleeding reduction was more pronounced in East Asians (HR: 0.35; 95% CI: 0.25-0.49; <em>P</em> &lt; 0.00001; <em>I</em>² = 0%) than non-East Asians (HR: 0.63; 95% CI: 0.43-0.93; <em>P</em> = 0.02; <em>I</em>² = 44%), with a significant interaction (<em>P</em> = 0.02). The abbreviation strategy significantly modified outcomes (<em>P</em> for interaction = 0.003): intensive abbreviation raised MACCE risk (HR: 1.37; 95% CI: 1.11-1.69; <em>P</em> = 0.003; <em>I</em>² = 0%), while moderate abbreviation had no statistically significant difference (HR: 0.96; 95% CI: 0.85-1.08; <em>P</em> = 0.47; <em>I</em>² = 0%).</div></div><div><h3>Conclusions</h3><div>In patients with ACS undergoing PCI, ultrashort DAPT reduced bleeding without increasing ischemic events overall, although a signal of increased MACCE was observed in STEMI but not in NSTE-ACS. Bleeding reduction was greater in East Asians, while ≤1-week DAPT or clopidogrel/aspirin monotherapy may increase ischemic risk.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2311-2329"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clopidogrel vs Aspirin According to Diabetes Mellitus","authors":"Sang Yoon Lee MD,&nbsp;Donghyeon Joo MD,&nbsp;Joo Myung Lee MD,&nbsp;Yong Hwan Park MD,&nbsp;Jong-Young Lee MD,&nbsp;Jin-Ok Jeong MD,&nbsp;Chan Joon Kim MD,&nbsp;Han Cheol Lee MD,&nbsp;Kiyuk Chang MD,&nbsp;Mahn-Won Park MD,&nbsp;Jang-Whan Bae MD,&nbsp;Joon-Hyung Doh MD,&nbsp;Byung Ryul Cho MD,&nbsp;Hee-Yeol Kim MD,&nbsp;Weon Kim MD,&nbsp;Ung Kim MD,&nbsp;Seung-Woon Rha MD,&nbsp;Young Joon Hong MD,&nbsp;Hyun-Jong Lee MD,&nbsp;Sung Gyun Ahn MD,&nbsp;Kyeong Ho Yun MD","doi":"10.1016/j.jcin.2026.05.013","DOIUrl":"10.1016/j.jcin.2026.05.013","url":null,"abstract":"<div><h3>Background</h3><div>Recent trials support the superior efficacy of clopidogrel compared to aspirin monotherapy after completion of dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI). However, limited evidence is available in patients with diabetes mellitus (DM).</div></div><div><h3>Objectives</h3><div>This study sought to evaluate the comparative efficacy and safety of clopidogrel vs aspirin monotherapy according to the presence of DM.</div></div><div><h3>Methods</h3><div>This was a prespecified analysis of the SMART-CHOICE 3 trial, which was a multicenter, open-label, randomized controlled trial comparing clopidogrel vs aspirin monotherapy in patients with complex coronary lesions or high-risk clinical characteristics. From August 2020 to July 2023, a total of 5,506 patients who underwent PCI and standard DAPT duration and had complex coronary lesions, DM, or previous myocardial infarction, were randomized to clopidogrel or aspirin monotherapy groups. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), which was defined as a composite of death from any cause, myocardial infarction, or stroke.</div></div><div><h3>Results</h3><div>Of 5,506 patients, 2,089 had DM (1,039 in the clopidogrel group and 1,050 in the aspirin group). At a median follow-up of 2.3 years (IQR: 1.6-3.0 years), DM patients had a higher risk of MACCE compared to non-DM patients (6.8% vs 4.7%; HR: 1.44, 95% CI: 1.10-1.87; <em>P</em> = 0.008). Clopidogrel showed a significantly lower risk of MACCE than aspirin in DM patients (4.5% vs 9.1%; HR: 0.57, 95% CI: 0.38-0.86; <em>P</em> = 0.008). There was no significant interaction between DM and antiplatelet monotherapy regarding MACCE (<em>P</em> for interaction = 0.124). The risk of bleeding was comparable between the 2 groups in DM patients (2.9% vs 2.9%; HR: 1.06, 95% CI: 0.57-1.95; <em>P</em> = 0.855).</div></div><div><h3>Conclusions</h3><div>Among DM patients who completed the standard duration of DAPT after PCI, clopidogrel monotherapy was associated with a lower risk of a composite of death from any cause, myocardial infarction, and stroke compared with aspirin monotherapy, without increased rates of bleeding. There was no significant interaction between DM and antiplatelet monotherapy with respect to MACCE. (SMART-CHOICE 3 [SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3]; <span><span>NCT04418479</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2333-2344"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148459802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preserve the Heart Team","authors":"Busra Cangut MD,&nbsp;Mateo Marin-Cuartas MD,&nbsp;Gilbert H.L. Tang MD, MSc, MBA","doi":"10.1016/j.jcin.2026.07.016","DOIUrl":"10.1016/j.jcin.2026.07.016","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2376-2379"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TAVR for Bicuspid Aortic Stenosis","authors":"Eric Van Belle MD, PhD,&nbsp;Louis Labrousse MD,&nbsp;Paul Guedeney MD, PhD,&nbsp;Philippe Pibarot MD, PhD","doi":"10.1016/j.jcin.2026.07.021","DOIUrl":"10.1016/j.jcin.2026.07.021","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2397-2399"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SCAI/ASE/HRS/SIR/SVS Expert Consensus Statement on Enhanced Radiation Protection","authors":"David G. Rizik MD, MSCAI,&nbsp;Nadia R. Sutton MD, MPH, FSCAI,&nbsp;Alexandra J. Lansky MD, MSCAI,&nbsp;Mirvat Alasnag MD, FSCAI,&nbsp;Gabriel Bartal MD,&nbsp;Mary Beth Brady MD,&nbsp;Megan Coylewright MD, MPH, FSCAI,&nbsp;James A. Goldstein MD, FSCAI,&nbsp;Scott M. Firestone MS,&nbsp;Andrew M. Goldsweig MD, MS, FSCAI,&nbsp;Dean J. Kereiakes MD, MSCAI,&nbsp;Melissa Kirkwood MD,&nbsp;Ryan D. Madder MD, FSCAI,&nbsp;Roxana Mehran MD, MSCAI,&nbsp;William J. Nicholson MD,&nbsp;Graciano Paulo PhD,&nbsp;Sunil V. Rao MD, MSCAI,&nbsp;Kenneth Rosenfield MD, MSCAI,&nbsp;Cheryl C. Schultz MS,&nbsp;Kamala P. Tamirisa MD,&nbsp;James B. Hermiller MD, MSCAI","doi":"10.1016/j.jcin.2026.06.011","DOIUrl":"10.1016/j.jcin.2026.06.011","url":null,"abstract":"<div><div>Health care professionals in fluoroscopic laboratories face significant occupational hazards, including cancer, cataracts, and reproductive concerns due to prolonged exposure to iodizing radiation, and orthopedic injuries stemming from long-term use of heavy aprons as protection from radiation. Despite substantial advancements in radiation protection technology, adoption of these advancements has been slow, hindered by the high upfront costs of implementation and the lag in revising institutional and regulatory radiation exposure thresholds to reflect the capabilities of contemporary enhanced radiation protection devices (ERPDs). This multisociety statement, endorsed by the Society for Cardiovascular Angiography &amp; Interventions, American College of Cardiology, the American Society of Echocardiography, the Heart Rhythm Society, the Society of Interventional Radiology, and the Society for Vascular Surgery, calls for mandatory implementation of ERPDs to meet as low as reasonably achievable standards. This expert consensus statement outlines the ethical and legal responsibilities of government, fluoroscopy laboratory manufacturers, and health care institutions to protect all health care professionals from avoidable workplace hazards and the urgent need to implement ERPDs. The document does not promote or recommend any single ERPD system, and the choice of protection technology is left to department preference. It also addresses the importance of training, monitoring, and continuous research to optimize radiation safety practices. The document advocates for updated regulations and standardized practices across states to ensure comprehensive protection for all fluoroscopy laboratory personnel.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2295-2310"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148432945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}